Health and Healthcare

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

307 Articles

Chris Lange | Aug 12, 2019 at 8:50 AM EDT

Short Sellers Make a Move on Big Biotechs

The July 31 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Jul 25, 2019 at 8:40 AM EDT

Major Biotechs See Rising Tide in Short Interest

The July 15 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Jul 11, 2019 at 9:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data…

Chris Lange | Jun 26, 2019 at 10:05 AM EDT

Big Biotechs Scare Off Short Sellers

The June 14 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Jun 12, 2019 at 8:40 AM EDT

Big Biotechs Have Short Sellers on the Run

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data…

Chris Lange | May 28, 2019 at 8:35 AM EDT

Major Biotechs See a Rising Tide in Short Interest

The May 15 short interest data have been compared with the previous report, and short interest in most of these…

Jon C. Ogg | May 23, 2019 at 11:40 AM EDT

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and…

Jon C. Ogg | May 23, 2019 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

The top analyst upgrades, downgrades and initiations seen on Thursday included AK Steel, Amgen, Booking, Chubb, Chipotle Mexican Grill, Expedia,…

Chris Lange | May 10, 2019 at 8:55 AM EDT

Short Sellers Back Off Major Biotechs

The April 30 short interest data have been compared with the previous report, and short interest in most of these…

Chris Lange | Apr 26, 2019 at 9:40 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The April 15 short interest data have been compared with the previous report, and short interest moves in these selected…

Jon C. Ogg | Apr 24, 2019 at 12:55 PM EDT

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top…

Chris Lange | Apr 10, 2019 at 9:15 AM EDT

Big Biotechs Confound Short Sellers

The March 29 short interest data have been compared with the previous report, and short interest moves in these selected…

Chris Lange | Mar 27, 2019 at 8:30 AM EDT

Big Biotechs Scare Off Short Sellers

The March 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Mar 12, 2019 at 9:05 AM EDT

Major Biotechs See a Rising Tide in Short Interest

The February 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Feb 28, 2019 at 8:35 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data…

1 … 3 4 5 6 7 … 21

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Make a Move on Big Biotechs

Major Biotechs See Rising Tide in Short Interest

Short Sellers Run for Cover From Major Biotechs

Big Biotechs Scare Off Short Sellers

Big Biotechs Have Short Sellers on the Run

Major Biotechs See a Rising Tide in Short Interest

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Short Sellers Back Off Major Biotechs

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Big Biotechs Confound Short Sellers

Big Biotechs Scare Off Short Sellers

Major Biotechs See a Rising Tide in Short Interest

Short Sellers Can’t Make Up Their Minds on Major Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Make a Move on Big Biotechs

Major Biotechs See Rising Tide in Short Interest

Short Sellers Run for Cover From Major Biotechs

Big Biotechs Scare Off Short Sellers

Big Biotechs Have Short Sellers on the Run

Major Biotechs See a Rising Tide in Short Interest

Citigroup Sees Big Upside for 2 of the Largest Biotechs

Top Analyst Upgrades and Downgrades: AK Steel, Amgen, Booking, Chubb, Chipotle, Expedia, Gilead, Goodyear, Philip Morris, Target, Zscaler and More

Short Sellers Back Off Major Biotechs

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Big Biotechs Confound Short Sellers

Big Biotechs Scare Off Short Sellers

Major Biotechs See a Rising Tide in Short Interest

Short Sellers Can’t Make Up Their Minds on Major Biotechs

‘Traders Need to Be Really Careful Here’: Schwab on the Fed Decision and Powell’s Uncertain Future

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

This Dividend ETF Is up 30% in 6 Months With a 3.7% Dividend Yield

Featured Reads

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Long-Term Care Could Cost This 68-Year-Old Couple $380,000 and Their $2.1 Million Portfolio Is Not Structured for It